U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Other Endocrine, CTCAE

MedGen UID:
286530
•Concept ID:
C1559206
•
Finding

Professional guidelines

PubMed

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.
Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, Tiberio P, Manara SAAM, Solferino A, Santoro A, De Sanctis R
Oncologist 2024 Jun 3;29(6):484-492. doi: 10.1093/oncolo/oyae004. PMID: 38242689Free PMC Article
Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
Hahner S, Hartrampf PE, Mihatsch PW, Nauerz M, Heinze B, Hänscheid H, Teresa Fuß C, Werner RA, Pamporaki C, Kroiss M, Fassnacht M, Buck AK, Schirbel A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1348-e1355. doi: 10.1210/clinem/dgab895. PMID: 34904171

Recent clinical studies

Etiology

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group
Lancet Oncol 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. PMID: 39214106
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.
Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA
Oncologist 2024 Jul 5;29(7):575-580. doi: 10.1093/oncolo/oyae099. PMID: 38776552Free PMC Article
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R
ESMO Open 2021 Oct;6(5):100231. Epub 2021 Sep 9 doi: 10.1016/j.esmoop.2021.100231. PMID: 34509802Free PMC Article
Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
Kanbayashi Y, Amaya F, Ueno H, Tabuchi Y, Ishikawa T, Takayama K, Taguchi T
Pharmazie 2021 Apr 1;76(4):175-178. doi: 10.1691/ph.2021.0959. PMID: 33849704
French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Endocr Relat Cancer 2019 Feb;26(2):G1-G18. doi: 10.1530/ERC-18-0320. PMID: 30400055Free PMC Article

Diagnosis

Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.
Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA
Oncologist 2024 Jul 5;29(7):575-580. doi: 10.1093/oncolo/oyae099. PMID: 38776552Free PMC Article
Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.
Barnabei A, Strigari L, Corsello A, Paragliola RM, Iannantuono GM, Salvatori R, Corsello SM, Torino F
Front Endocrinol (Lausanne) 2022;13:840971. Epub 2022 Mar 21 doi: 10.3389/fendo.2022.840971. PMID: 35388297Free PMC Article
Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
Hahner S, Hartrampf PE, Mihatsch PW, Nauerz M, Heinze B, Hänscheid H, Teresa Fuß C, Werner RA, Pamporaki C, Kroiss M, Fassnacht M, Buck AK, Schirbel A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1348-e1355. doi: 10.1210/clinem/dgab895. PMID: 34904171
French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Endocr Relat Cancer 2019 Feb;26(2):G1-G18. doi: 10.1530/ERC-18-0320. PMID: 30400055Free PMC Article
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Ann Endocrinol (Paris) 2018 Oct;79(5):591-595. Epub 2018 Jul 11 doi: 10.1016/j.ando.2018.07.005. PMID: 30056975

Therapy

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group
Lancet Oncol 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. PMID: 39214106
Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.
Barnabei A, Strigari L, Corsello A, Paragliola RM, Iannantuono GM, Salvatori R, Corsello SM, Torino F
Front Endocrinol (Lausanne) 2022;13:840971. Epub 2022 Mar 21 doi: 10.3389/fendo.2022.840971. PMID: 35388297Free PMC Article
Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
Kanbayashi Y, Amaya F, Ueno H, Tabuchi Y, Ishikawa T, Takayama K, Taguchi T
Pharmazie 2021 Apr 1;76(4):175-178. doi: 10.1691/ph.2021.0959. PMID: 33849704
French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Endocr Relat Cancer 2019 Feb;26(2):G1-G18. doi: 10.1530/ERC-18-0320. PMID: 30400055Free PMC Article
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F
Ann Endocrinol (Paris) 2018 Oct;79(5):591-595. Epub 2018 Jul 11 doi: 10.1016/j.ando.2018.07.005. PMID: 30056975

Prognosis

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.
Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, Tiberio P, Manara SAAM, Solferino A, Santoro A, De Sanctis R
Oncologist 2024 Jun 3;29(6):484-492. doi: 10.1093/oncolo/oyae004. PMID: 38242689Free PMC Article
Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
Hahner S, Hartrampf PE, Mihatsch PW, Nauerz M, Heinze B, Hänscheid H, Teresa Fuß C, Werner RA, Pamporaki C, Kroiss M, Fassnacht M, Buck AK, Schirbel A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1348-e1355. doi: 10.1210/clinem/dgab895. PMID: 34904171
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R
ESMO Open 2021 Oct;6(5):100231. Epub 2021 Sep 9 doi: 10.1016/j.esmoop.2021.100231. PMID: 34509802Free PMC Article
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, Mehra N, Bins A, Hunting J, de Keizer B
Clin Nucl Med 2019 Jun;44(6):446-451. doi: 10.1097/RLU.0000000000002561. PMID: 30985436

Clinical prediction guides

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group
Lancet Oncol 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. PMID: 39214106
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.
Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA
Oncologist 2024 Jul 5;29(7):575-580. doi: 10.1093/oncolo/oyae099. PMID: 38776552Free PMC Article
Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
Hahner S, Hartrampf PE, Mihatsch PW, Nauerz M, Heinze B, Hänscheid H, Teresa Fuß C, Werner RA, Pamporaki C, Kroiss M, Fassnacht M, Buck AK, Schirbel A
J Clin Endocrinol Metab 2022 Mar 24;107(4):e1348-e1355. doi: 10.1210/clinem/dgab895. PMID: 34904171
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R
ESMO Open 2021 Oct;6(5):100231. Epub 2021 Sep 9 doi: 10.1016/j.esmoop.2021.100231. PMID: 34509802Free PMC Article
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM
Oncologist 2019 Nov;24(11):e1024-e1033. Epub 2019 Apr 25 doi: 10.1634/theoncologist.2017-0664. PMID: 31023863Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...